Mutations in genes encoding epigenetic modifiers are frequent in acute myelogenous leukemia (AML) and have been proposed to cause AML via activation of oncogenes and repression of tumor suppressors. Two studies now identify unexpected oncogenic mechanisms and therapeutic vulnerabilities in AML arising from mutations in genes encoding the epigenetic regulators DNMT3A and ASXL1.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The Cancer Genome Atlas Research Network. N. Engl. J. Med. 368, 2059–2074 (2013).
Shlush, L. I. et al. Nature 506, 328–333 (2014).
Ueda, K. et al. Cancer Cell 39, 529–547 (2021).
Park, S. J. & Bejar, R. Exp. Hematol. 83, 105–112 (2020).
Scheller, M. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00213-9 (2021).
Wang, L. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00199-4 (2021).
Chaudry, S. F. & Chevassut, T. J. BioMed Res. Int. 2017, 5473197 (2017).
Russler-Germain, D. A. et al. Cancer Cell 25, 442–454 (2014).
Baylin, S. B. & Jones, P. A. Nat. Rev. Cancer 11, 726–734 (2011).
Treppendahl, M. B., Kristensen, L. S. & Gronbaek, K. J. Clin. Invest. 124, 47–55 (2014).
Muller-Tidow, C. et al. Leukemia 30, 555–561 (2016).
Chiappinelli, K. B. et al. Cell 162, 974–986 (2015).
Roulois, D. et al. Cell 162, 961–973 (2015).
Wolff, F., Leisch, M., Greil, R., Risch, A. & Pleyer, L. Cell Commun. Signal. 15, 13 (2017).
Asada, S., Fujino, T., Goyama, S. & Kitamura, T. Cell. Mol. Life Sci. 76, 2511–2523 (2019).
Abdel-Wahab, O. et al. Cancer Cell 22, 180–193 (2012).
Pietras, E. M. Blood 130, 1693–1698 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
U.S. reports research support and personal fees from Bayer Healthcare; personal fees from Celgene; research support from GlaxoSmithKline; research support and personal fees from Aileron Therapeutics; personal fees and involvement as scientific cofounder and member on the board of directors of Stelexis Therapeutics; personal fees from Pieris Pharmaceuticals; personal fees from Novartis; and personal fees from Vor Biopharma outside the submitted work.
Rights and permissions
About this article
Cite this article
Ueda, K., Steidl, U. Epigenetic Achilles’ heel of AML. Nat Cancer 2, 481–483 (2021). https://doi.org/10.1038/s43018-021-00212-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00212-w